Combined Radiation and Endocrine Therapies Elicit Benefit in ER+ Breast Cancer.

ABSTRACT:

Background

Standard treatment for patients with early-stage estrogen receptor-positive (ER+) breast cancer often includes sequential adjuvant radiation and endocrine therapies. Unfortunately, ~1/3 of patients eventually experience disease recurrence, partly due to residual disease in the form of drug-tolerant persister cancer cells. The anti-cancer efficacy of radiation therapy is partly attributable to the production of oxyradicals that damage biomolecules. We previously showed that endocrine therapy increases mitochondrial content in ER+ breast cancer cells; we postulated that this may also increase oxidative stress.

Methods

Herein, we tested the efficacy of concurrent endocrine and radiation therapies, including both conventional (CDR) and ultra-high dose rate (UHDR) radi

SUBMITTER: Johnson AL 

PROVIDER: S-EPMC12190792 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature